tiprankstipranks
Advertisement
Advertisement
Buy Rating Reaffirmed on CAMP4 as CMP-002 Advances Toward 2026 SYNGAP1 Trial and Strong Cash Runway Extends Into 2028
PremiumRatingsBuy Rating Reaffirmed on CAMP4 as CMP-002 Advances Toward 2026 SYNGAP1 Trial and Strong Cash Runway Extends Into 2028
2M ago
Camp4 Therapeutics reports Q1 EPS (32c), consensus (21c)
Premium
The Fly
Camp4 Therapeutics reports Q1 EPS (32c), consensus (21c)
2M ago
Camp4 Therapeutics initiated with a Buy at Rodman & Renshaw
Premium
The Fly
Camp4 Therapeutics initiated with a Buy at Rodman & Renshaw
3M ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
4M ago
CAMP4 Highlights 2025 Results and SYNGAP1 Program Progress
Premium
Company Announcements
CAMP4 Highlights 2025 Results and SYNGAP1 Program Progress
4M ago
Camp4 Therapeutics participates in a conf call hosted by Cantor Fitzgerald
Premium
The Fly
Camp4 Therapeutics participates in a conf call hosted by Cantor Fitzgerald
5M ago
External Validation and Strengthened Balance Sheet Underpin Buy Rating on CAMP4 Therapeutics
PremiumRatingsExternal Validation and Strengthened Balance Sheet Underpin Buy Rating on CAMP4 Therapeutics
7M ago
CAMP4, GSK form RNA therapeutics collaboration agreement
Premium
Company Announcements
CAMP4, GSK form RNA therapeutics collaboration agreement
7M ago
Camp4 Therapeutics prices 5M shares at $6.00 in underwritten public offering
Premium
The Fly
Camp4 Therapeutics prices 5M shares at $6.00 in underwritten public offering
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100